Approved Use

KYPROLIS® (carfilzomib) is a prescription medication used to treat adult patients with relapsed or refractory multiple myeloma who have received one to three previous treatments for multiple myeloma... Read More

Are you a healthcare professional?

The information provided in this section is intended expressly for healthcare professionals in the United States. Click “Yes, I am” to enter if you are a U.S. healthcare professional.

3-0_hero_composite-jpg 1-0_hero_composite_m-jpg
Step 3
Relapse happens.
But so does [re]remission

Seeing that my labs were actually changing by using KYPROLIS® put me in a better way that we were going the right direction. In my case, I went into complete remission with KYPROLIS®.

In clinical trials, KYPROLIS® has been proven to help patients with multiple myeloma live longer without their disease getting worse and reach a complete response* or better.

*Complete response is defined as no detectable M-proteins in the blood and urine, less than 5% abnormal plasma cells in bone marrow, and no detectable plasma cell tumors.

KYPROLIS® works hard to get you through relapse and back to focusing on your life, not your disease

Results for KYPROLIS® + DARZALEX®* + dexamethasone

kdd_graphic_8_10_patients-svg

Over 8 out of 10 patients

responded to KYPROLIS® + DARZALEX® + dexamethasone
(84% vs 75% with Kd alone)

kdd_graphic_2_5x-svg

as many patients on KYPROLIS® + DARZALEX® + dexamethasone

achieved a complete response than with Kd alone
(28% vs 10%)

*DARZALEX® (daratumumab).

Response was defined as partial response or better.

In a clinical study of 466 patients with relapsed or refractory multiple myeloma who had received 1 to 3 prior lines of therapy, 312 patients received KYPROLIS® in combination with DARZALEX® and dexamethasone, and 154 received KYPROLIS® in combination with dexamethasone. The study compared how long patients lived without their disease getting worse. The median follow-up was nearly 28 months.

§In an earlier analysis with a median follow-up of ~17 months, the median progression-free survival (the length of time from the start of treatment until half of patients had experienced disease progression or death) had not been reached with KYPROLIS® + DARZALEX® (daratumumab) + dexamethasone vs 15.8 months with Kd alone.

Kd = KYPROLIS® + dexamethasone; M-proteins = monoclonal proteins.

Complete response is defined as no detectable M-proteins in the blood and urine, less than 5% abnormal plasma cells in bone marrow, and no detectable plasma cell tumors.

Median is the middle value in a list of values arranged from low to high such that there are the same number of values above and below this middle value.

DARZALEX® (daratumumab) is a registered trademark of Johnson & Johnson Corporation New Jersey.

Results for KYPROLIS® + Rd (Revlimid® + dexamethasone)

krd_graphic_9_10_patients-svg

Almost 9 out of 10 patients

responded to KYPROLIS® + Rd
(87% vs 67% with Rd alone)*

krd_graphic_3x-svg

as many patients on KYPROLIS® + Rd

achieved a complete response or
better than with Rd alone (32% vs 9%)

*Response was defined as partial response or better.

In a clinical study of 792 patients with relapsed or refractory multiple myeloma who had received 1 to 3 prior lines of therapy, 396 patients received KYPROLIS® in combination with Revlimid® and dexamethasone, and 396 received Revlimid® in combination with dexamethasone. The study compared how long patients lived without their disease getting worse as well as how long they lived overall.

Complete response is defined as no detectable M‑proteins in the blood and urine, less than 5% abnormal plasma cells in bone marrow, and no detectable plasma cell tumors.

Median is the middle value in a list of values arranged from low to high such that there are the same number of values above and below this middle value.

Revlimid® (lenalidomide) is a registered trademark of Celgene.

Results for once-weekly KYPROLIS® + d (dexamethasone)

kd_1_graphic_more_patients-svg

Over 6 out of 10 patients

responded to once-weekly KYPROLIS® + d than with twice-weekly KYPROLIS® + d (63% vs 41%)*

kd_1_graphic_4x-svg

as many patients on once-weekly KYPROLIS® + d

achieved a complete response or better (7.1% vs 1.7% with twice-weekly KYPROLIS® + d)

* Response was defined as partial response or better.

In a clinical study of 478 patients with relapsed and refractory multiple myeloma who had received 2 to 3 prior lines of therapy, 240 patients received KYPROLIS® at 70 mg/m2 in combination with dexamethasone once weekly, and 238 patients received KYPROLIS® at 27 mg/m2 in combination with dexamethasone twice weekly. The study compared how long patients lived without their disease getting worse.

Complete response is defined as no detectable M-proteins in the blood and urine, less than 5% abnormal plasma cells in bone marrow, and no detectable plasma cell tumors.

Median is the middle value in a list of values arranged from low to high such that there are the same number of values above and below this middle value.

27 mg/m2 is not an FDA-approved dose for KYPROLIS® in combination with dexamethasone alone.

Results for twice-weekly KYPROLIS® + d (dexamethasone)

kd_2_graphic_8_10_patients-svg

Almost 8 out of 10 patients

responded to
twice-weekly KYPROLIS® + d
(77% vs 63% Velcade® + d [Vd])*

kd_2_graphic_2x-svg

as many patients on twice-weekly KYPROLIS® + d

achieved a complete response or better than with Vd (13% vs 6%)

* Response was defined as partial response or better.

In a clinical study of 929 patients with relapsed or refractory multiple myeloma who had received 1 to 3 prior lines of therapy, 464 patients received KYPROLIS® in combination with dexamethasone, and 465 received Velcade® in combination with dexamethasone. The study compared how long patients lived without their disease getting worse as well as how long they lived overall.

Complete response is defined as no detectable M-proteins in the blood and urine, less than 5% abnormal plasma cells in bone marrow, and no detectable plasma cell tumors.

Median is the middle value in a list of values arranged from low to high such that there are the same number of values above and below this middle value.

Velcade® (bortezomib) is a registered trademark of Millennium Pharmaceuticals.

img_yolanda_video_banner-jpg

Yolanda achieved [re]remission with the help of KYPROLIS®

Hear her story

Individual results may vary.

Next: What to expect with KYPROLIS® treatment

IMPORTANT SAFETY INFORMATION

KYPROLIS® (carfilzomib) can cause serious side effects:

  • Heart problems: KYPROLIS can cause heart problems or worsen pre-existing heart conditions. Death due to cardiac arrest has occurred within one day of KYPROLIS administration. Before starting KYPROLIS, you should have a full medical work-up (including blood pressure and fluid management). You should be closely monitored during treatment.
  • Kidney problems: There have been reports of sudden kidney failure in patients receiving KYPROLIS. Your kidney function should be closely monitored during treatment.
  • Tumor lysis syndrome (TLS): Cases of TLS have been reported in patients receiving KYPROLIS, including fatalities. You should be closely monitored during treatment for any signs of TLS.
  • Lung damage: Cases of lung damage have been reported in patients receiving KYPROLIS, including fatal cases.
  • Pulmonary hypertension (high blood pressure in the lungs): There have been reports of pulmonary hypertension in patients receiving KYPROLIS.
  • Lung complications: Shortness of breath was reported in patients receiving KYPROLIS. Your lung function should be closely monitored during treatment.
  • High blood pressure: Cases of high blood pressure, including fatal cases, have been reported in patients receiving KYPROLIS. Your blood pressure should be closely monitored during treatment.
  • Blood clots: There have been reports of blood clots in patients receiving KYPROLIS. If you are at high risk for blood clots, your doctor can recommend ways to lower the risk.
  • If you are using KYPROLIS in combination with dexamethasone or with lenalidomide plus dexamethasone or with daratumumab and dexamethasone, your doctor should assess and may prescribe another medicine to help lower your risk for blood clots.
  • If you are using birth control pills or other medical forms of birth control associated with a risk of blood clots, talk to your doctor and consider a different method of birth control during treatment with KYPROLIS in combination with dexamethasone, with lenalidomide plus dexamethasone, or with daratumumab and dexamethasone.
  • Infusion-related reactions: Signs and symptoms of infusion-related reactions included fever, chills, joint pain, muscle pain, facial flushing and/or swelling, swelling of the larynx (voice box), vomiting, weakness, shortness of breath, low blood pressure, fainting, chest tightness, and chest pain. These symptoms can occur immediately following infusion or up to 24 hours after administration of KYPROLIS. If you experience any of these symptoms, contact your doctor immediately.
  • Severe bleeding problems: Fatal or serious cases of bleeding problems have been reported in patients receiving KYPROLIS. Your doctor should monitor your signs and symptoms of blood loss.
  • Very low platelet count: Low platelet levels can cause unusual bruising and bleeding. You should have regular blood tests to check your platelet count during treatment.
  • Liver problems: Cases of liver failure, including fatal cases, have been reported in patients receiving KYPROLIS. Your liver function should be closely monitored during treatment.
  • Blood problems: Cases of a blood disease called thrombotic microangiopathy, including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), including fatal cases, have been reported in patients who received KYPROLIS. Your doctor should monitor your signs and symptoms.
  • Brain problems: A nerve disease called Posterior Reversible Encephalopathy Syndrome (PRES), formerly called Reversible Posterior Leukoencephalopathy Syndrome (RPLS), has been reported in patients receiving KYPROLIS. It can cause seizure, headache, lack of energy, confusion, blindness, altered consciousness, and other visual and nerve disturbances, along with high blood pressure. Your doctor should monitor your signs and symptoms.
  • Cases of a brain infection called Progressive Multifocal Leukoencephalopathy (PML), including fatal cases, have been reported in patients receiving KYPROLIS. Your doctor should monitor your signs and symptoms.
  • KYPROLIS should not be combined with melphalan and prednisone: Newly diagnosed transplant ineligible multiple myeloma patients have shown an increased risk of serious and fatal side effects when using KYPROLIS in combination with melphalan and prednisone.
  • Possible fetal harm: KYPROLIS can cause harm to a fetus (unborn baby) when given to a pregnant woman. Women should use effective contraception during treatment with KYPROLIS and for 6 months following the final dose. Men should use effective contraception during treatment with KYPROLIS and for 3 months following the final dose. KYPROLIS can cause harm to a fetus if used during pregnancy or if you or your partner become pregnant during treatment with KYPROLIS.
You should contact your doctor immediately if you experience any of the following:
  • Shortness of breath
  • Prolonged, unusual or excessive bleeding
  • Yellowing of the skin and/or eyes (jaundice)
  • Headaches, confusion, seizures, or loss of sight
  • Pregnancy (women should not receive KYPROLIS if they are pregnant or breastfeeding)
  • Any other side effect that bothers you or does not go away
What are the possible side effects of KYPROLIS?
  • The most common side effects occurring in at least 20% of patients receiving KYPROLIS in the combination therapy trials are: low red blood cell count, diarrhea, tiredness (fatigue), high blood pressure (hypertension), fever, upper airway (respiratory tract) infection, low platelets, cough, difficulty breathing and sleeplessness (insomnia).

These are not all the possible side effects of KYPROLIS. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088. 1‑800‑FDA‑1088.

Please see full Product Information.

APPROVED USE

  • KYPROLIS® (carfilzomib) is a prescription medication used to treat adult patients with relapsed or refractory multiple myeloma who have received one to three previous treatments for multiple myeloma. KYPROLIS is approved for use in combination with daratumumab plus dexamethasone, dexamethasone or with lenalidomide plus dexamethasone, which are other medicines used to treat multiple myeloma.